Table 4

Plasma peptide content in relation to tumor development in three Ewing sarcoma patients

Plasma sampleEwing sarcoma tumor size (mm3)Plasma peptide content (pmol/L)
CCK-amideproCCK
Patient no. 1 (1ZEW)
 Before therapy144,0000.919.6
 After 3 months chemotherapy3,7502.67.8
 After tumor recurrence95,0000.5100.0
Patient no. 2 (2REW)
 Before therapy31,5001.734.0
 After 3.5 months chemotherapy5,6251.06.0
 After 9 months chemotherapy03.010.0
 After 12 months chemotherapy01.820.4
 After 15 months chemotherapy00.311.1
 After 18 months chemotherapy01.96.5
Patient no. 3 (3HEW)
 Before therapy≫100,0002.935.0
 After 8 months therapy00.87.2
Control values (normal young adults; n = 13, mean ± SE)1.1 ± 0.15.3 ± 0.6
Non-Ewing tumor patients (before therapy; n = 6, mean ± SE)2.2 ± 0.89.9 ± 1.4